Effects of canagliflozin on amputation risk in type 2 diabetes: The CANVAS Program

Diabetologia

Volumn 62, Issue 6, 2019, Pages 926-938

  Matthews, David R ^a,b   Li, Qiang ^c   Perkovic, Vlado ^c,d   Mahaffey, Kenneth W ^e   de Zeeuw, Dick ^f   Fulcher, Greg ^d   Desai, Mehul ^g   Hiatt, William R ^h   Nehler, Mark ^h   Fabbrini, Elisa ^g   Kavalam, Mary ^g   Lee, Mary ^g   Neal, Bruce ^c,i  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^g JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^h UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

ⁱ IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Clinical diabetes; Clinical science; Diabetic foot; Human; Oral pharmacological agents

Indexed keywords

ANTIDIABETIC AGENT; CANAGLIFLOZIN;

AGED; AMPUTATION; CONTROLLED STUDY; DIABETIC FOOT; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; AGED; AMPUTATION; CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 2; DIABETIC FOOT; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS;

EID: 85062982295     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-019-4839-8     Document Type: Article

References (20)

1. Cefalu WT, Leiter LA, Yoon KH et al (2013) Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 382(9896):941-950. https://doi.org/10.1016/S0140-6736(13)60683-2
2. Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377(7):644-657. https://doi.org/10.1056/NEJMoa1611925
3. Neal B, Perkovic V, de Zeeuw D etal (2013) Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)-a randomized placebo-controlled trial. Am Heart J 166(2):217-223 e211. https://doi.org/10.1016Zj.ahj.2013.05.007
4. Neal B, Perkovic V, Matthews DR et al (2017) Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): a randomized, placebo-controlled trial. Diabetes Obes Metab 19(3):387-393. https://doi.org/10.1111/dom.12829
5. Neal B, Perkovic V, Mahaffey KW et al (2017) Optimizing the analysis strategy for the CANVAS Program: a prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials. Diabetes Obes Metab 19(7):926-935. https://doi.org/10.1111/dom.12924
6. Janssen Inc (2017) Product monograph-C. Available from https://www.drugs.com/monograph/canagliflozin.html. Accessed 26 June 2018
7. STEGLATRO™ [package insert] (2017) Whitehouse Station, NJ: Merck Sharp & Dohme Corp
8. Yuan Z, Defalco FJ, Ryan PB et al (2018) Risk of lower extremity amputations in patients with type 2 diabetes mellitus treated with SGLT2 inhibitors in the United States: a retrospective cohort study. Diabetes Obes Metab 20(3):582-589. https://doi.org/10.1111/dom.13115
9. Inzucchi SE, Iliev H, Pfarr E, Zinman B (2018) Empagliflozin and assessment of lower-limb amputations in the EMPA-REG OUTCOME trial. Diabetes Care 41(1):e4-e5. https://doi.org/10.2337/dc17-1551
10. Radholm K, Wu JH, Wong MG et al (2018) Effects of sodiumglucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes-a systematic review. Diabetes Res Clin Pract 140:118-128. https://doi.org/10.10167j.diabres.2018.03.027
11. Jardine MJ, Mahaffey KW, Neal B etal (2017) The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study rationale, design, and baseline characteristics. Am J Nephrol 46(6):462-472. https://doi.org/10.1159/000484633
12. Ryan PB, Buse JB (2018) Comp arative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: a real-world meta-analysis of 4 observational databases (OBSERVE-4D). Diabetes Obes Metab 20(11):2585-2597. https://doi.org/10.1111/dom.13424
13. Udell JA, Yuan Z, Rush T, Sicignano NM, Galitz M, Rosenthal N (2018) Cardiovascular outcomes and risks after initiation of a sodium glucose co-transporter 2 inhibitor: results from the EASEL population-based cohort study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World). Circulation 137(14):1450-1459. https://doi.org/10.1161/CIRCULATIONAHA.117.031227
14. Khouri C, Cracowski JL, Roustit M (2018) SGLT-2 inhibitors and the risk of lower-limb amputation: Is this a class effect? Diabetes Obes Metab 20(6):1531-1534. https://doi.org/10.1111/dom.13255
15. Fadini GP, Avogaro A (2017) SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System. Lancet Diabetes Endocrinol 5(9):680-681. https://doi.org/10.1016/S2213-8587(17)30257-7
16. Ueda P, Svanstrom H, Melbye M et al (2018) Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ 363:k4365
17. U.S. Food & Drug Administration (2017) FDA Drug Safety Communication: FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR). Available from https://www.fda.gov/downloads/Drugs/DrugSafety/UCM558427.pdf. Accessed 9 August 2017
18. European Medicines Agency (2017) PRAC assessment report. Available from http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/SGLT2_inhibitors_Canagliflozin_20/European_Commission_final_decision/WC500227102.pdf. Accessed 16 June 2017
19. Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):2117-2128. https://doi.org/10.1056/NEJMoa1504720
20. Kohler S, Zeller C, Iliev H, Kaspers S (2017) Safety and tolerability of empagliflozin in patients with type 2 diabetes: pooled analysis of phase I-III clinical trials. Adv Ther 34(7):1707-1726. https://doi.org/10.1007/s12325-017-0573-0